Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Escitalopram and nortriptyline versus placebo for depression in Parkinson's disease
ISRCTN48548553Phase 3Completed
- Sponsor
- University College London
- Start
- Nov 2020
- Modality
- Small Molecules
01
Overview
Phase 3, randomised trial in major depressive disorder (MDD) and depression in Parkinson's disease comparing Escitalopram, Nortriptyline and Placebo (3 arms). Primary endpoint: Primary: Depressive symptoms by Beck Depression Inventory-II. Started Nov 2020; status: completed.
02
Drugs
escitalopramnortriptyline
03
Conditions
major depressive disorder (MDD)depression in Parkinson's disease
Beyond the preview
Go deeper on ISRCTN48548553.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN48548553.